No Data
Nkarta Shares Are Trading Higher After the Company Announced an Agreement With the FDA on Protocols for Its Ntrust-1 and Ntrust-2 Clinical Trials.
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Analysts Are Bullish on These Healthcare Stocks: Nkarta (NKTX), Harrow Health (HROW)
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11
Analysts' Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)
H.C. Wainwright Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $16